

July 31, 2025

National Stock Exchange of India Limited

Exchange Plaza,

Plot No. C/1, G Block,

Bandra Kurla Complex, Bandra (E)

Mumbai – 400 051

BSE Limited

Corporate Relationship Department

Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai - 400 001

Symbol: LALPATHLAB Scrip Code: 539524

Sub: <u>Press Release on Un-audited Financial Results (Standalone and Consolidated)</u> <u>for the Quarter ended June 30, 2025</u>

Dear Sir/ Madam,

Please find enclosed herewith the Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2025.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited

Vinay Gujral
Company Secretary & Compliance Officer

Encl.: As above



For Immediate Release July 31, 2025

Dr Lal PathLabs Limited records revenue of Rs 670 Cr in Q1 FY 2025-26

New Delhi, India, July 31, 2025 – Dr Lal PathLabs Limited (referred to as the "Company"; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended June 30, 2025.

Consolidated Performance Highlights: Q1 FY26 vs Q1 FY25

- Revenue increased by 11.3% in Q1 FY26
- EBITDA increased by 13.1% with a margin of 28.7%
- PAT increased by 24.3% with a margin for of 20.0%
- Interim Dividend of Rs. 6 per share for Q1 FY26

Financial Overview (Consolidated) in Rs Cr

Particulars	Q1		
	FY26	FY25	Gr %
Revenue	670	602	11.3%
Material consumed	129	119	
Employee benefit Expenses	132	117	
Fees to collection centres	92	84	
Other Expenses	124	112	
EBITDA	192	170	13.1%
Margins	28.7%	28.2%	
Other Income	28	21	
Depreciation Cost	35	35	
Finance Cost	5	6	
PBT	181	150	20.8%
Margins	27.0%	24.9%	
PAT	134	108	24.3%
Margins	20.0%	17.9%	
EPS	15.9	12.8	24.4%

About Dr Lal PathLabs Limited

Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

Dr Lal Pathlabs Limited



As on March 31, 2025 the company has 298 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 6,607 Patient Service Centers (PSCs) and 12,365 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Goel
Group Chief Financial Officer
Dr Lal PathLabs Limited

+91 124 3016500 cfo@lalpathlabs.com

Kritika Khatwani *Adfactors PR*

+91 8604801332 kritika.khatwani@adfactorspr.com

For further information on Dr Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.